Shigella Statistics in US 2026 | Shigella Outbreak Facts

Shigella Outbreak in America 2026

Shigella — the bacterium behind the gut-wrenching illness known as shigellosis — is quietly staging one of its most alarming comebacks in American public health history. What used to be a disease primarily associated with young children in daycare settings has, as of 2026, transformed into something far more complex and dangerous. The Centers for Disease Control and Prevention (CDC) published landmark findings in the Morbidity and Mortality Weekly Report (MMWR) on April 9, 2026, confirming that extensively drug-resistant (XDR) Shigella infections have risen from 0% of all isolates in 2011 to 8.5% in 2023 — a jaw-dropping trajectory that has public health officials sounding the alarm. With no FDA-approved oral treatment currently available for XDR strains, the American healthcare system is facing a growing crisis with limited tools to fight back.

What makes the 2026 Shigella outbreak situation in the United States particularly urgent is the dramatic shift in who is being affected. Historically, shigellosis hit children hardest — especially those aged 1 to 4 years in childcare settings. Today, the CDC’s latest surveillance data tells a starkly different story: the majority of XDR Shigella cases in 2026 are occurring among adult men, with a median patient age of 41 years. Nearly half of those tested show HIV co-infection, pointing to a disease that has embedded itself deeply within immunocompromised communities and is spreading through domestic transmission networks. With an estimated 450,000 shigellosis cases occurring in the United States every year, understanding the full scope of this outbreak — its statistics, its shifting demographics, and its drug-resistance profile — has never been more critical.

Interesting Facts About Shigella in the US 2026

Before diving into the numbers, here are some of the most striking facts about Shigella in America in 2026 that every American should know. These are not scare tactics — they are CDC-confirmed, surveillance-backed realities.

Source: CDC Morbidity and Mortality Weekly Report (MMWR), April 9, 2026; CDC Clinical Overview of Shigellosis; CDC National Outbreak Reporting System (NORS); Frontiers in Public Health, February 2026

The facts above paint a clear and deeply concerning picture of where Shigella in America stands in 2026. The bacterium has long been underestimated, often dismissed as a traveler’s nuisance or a daycare inconvenience. But with nearly a quarter-million drug-resistant cases estimated annually, and with XDR strains now composing 8.5% of all tested isolates, the disease has crossed a threshold that demands serious public attention. The sheer virulence of this pathogen — needing as few as 10 bacterial organisms to trigger full infection — combined with its weeks-long shedding period, creates conditions where community transmission can spiral rapidly even when people feel fine.

Perhaps most alarming is the financial and human cost. With annual US shigellosis-related direct medical costs reaching an estimated $93 million, and with ~1 in 3 XDR patients requiring hospitalization, the burden on the healthcare system is tangible and growing. The absence of any FDA-approved oral antimicrobial for XDR strains means clinicians are navigating treatment blindfolded, relying on IV options and case-by-case consultations with infectious disease specialists. This is not a future problem — it is the reality on the ground right now in 2026.

Shigella Annual Case Counts in the US 2026 | Shigellosis Surveillance Data 2026

The year-by-year surveillance data reported through CDC’s National Notifiable Diseases Surveillance System (NNDSS) tells a revealing story of how Shigella case volumes have fluctuated in recent years — and why 2026 demands continued vigilance.

Source: CDC National Notifiable Diseases Surveillance System (NNDSS); CDC MMWR, April 9, 2026; Vax-Before-Travel citing CDC surveillance data, 2025

The upward trajectory of reported shigellosis cases in the United States is unmistakable. From a 2023 reported total of 17,176 cases, numbers jumped to 20,621 in 2024 — a year-over-year increase that signals sustained, high-volume domestic transmission rather than isolated outbreak clusters. California and New York have consistently led state-level case counts, reflecting the influence of dense urban populations, higher rates of homelessness, and robust surveillance infrastructure that captures more cases than less-resourced states. Early 2025 data showing 2,352 cases by March alone suggests that 2025 annual totals likely followed a similar high-burden trajectory.

What these reported numbers do not fully capture, however, is the massive scale of unreported shigellosis in America. The CDC estimates 450,000 total annual infections, meaning the vast majority — potentially more than 95% of all cases — never make it into official surveillance tallies. People recover at home within 5 to 7 days, never seek care, and never get counted. This surveillance gap is exactly why the confirmed case numbers above represent only the tip of the iceberg. Understanding the real burden requires combining reported data with CDC’s broader estimation models — and by that measure, shigellosis in 2026 remains one of the most widespread and underappreciated bacterial infections in the country.

XDR Shigella Drug Resistance Statistics in the US 2026 | Antibiotic Resistance Facts 2026

The most urgent development in the shigella outbreak in the US in 2026 is not just how many people are getting infected — it is the growing inability of standard antibiotics to treat those infections. CDC’s April 2026 MMWR laid out the resistance landscape in stark detail.

Source: CDC MMWR, April 9, 2026 — “Emergence of Extensively Drug-Resistant Shigellosis — United States, 2011–2023,” Vol. 75, No. 13, pp. 173–178

The resistance data is where the shigella statistics in the US in 2026 become genuinely frightening. In the span of roughly a decade, XDR Shigella went from being nonexistent in US surveillance to comprising 8.5% of all tested isolates by 2023 — and the MMWR notes the trend is continuing upward. What makes this especially dangerous is the species composition: Shigella flexneri, which is disproportionately represented among XDR cases at 34.1% compared to its 18.5% share in overall US surveillance, is associated with more severe clinical outcomes including dysentery, higher hospitalization rates, and a greater case-fatality rate compared to S. sonnei. The combination of XDR resistance and the more virulent S. flexneri species creates a worst-case clinical scenario.

The fact that approximately 242,000 of the estimated 450,000 annual US shigellosis cases are already antimicrobial-resistant — not just XDR but broadly drug-resistant — underscores how widespread resistance has become across the full spectrum of Shigella infections. When no FDA-approved oral antimicrobial exists for the worst-case strain, clinicians are left with IV options that require hospitalization, specialist consultation, and significantly higher treatment costs. This treatment gap is precisely why early detection, susceptibility testing, and timely public health reporting are so heavily emphasized by the CDC in 2026.

Shigella Demographics and At-Risk Groups in the US 2026 | Who Gets Shigella 2026

One of the most striking findings from recent CDC surveillance is how dramatically the demographic profile of Shigella in the United States has changed over the past decade. The data below reflects what the April 2026 MMWR and supporting CDC NORS data reveal about who is being hit hardest.

Source: CDC MMWR, April 9, 2026; CDC National Outbreak Reporting System (NORS); Frontiers in Public Health, February 2026 (Bajwa, Adegbole, Smith)

The demographic data tells a story of a disease in transition. Traditional shigellosis in America was predominantly a pediatric problem — children aged 1 to 4 years in childcare settings bore the highest outbreak incidence from 2009 through 2018, as consistently reported through CDC NORS. But XDR Shigella has flipped that script entirely. With 86.2% of XDR cases occurring in men, a median age of 41, and nearly half of tested patients carrying HIV co-infection, the disease has become heavily concentrated in adult immunocompromised networks. The near-complete absence of recent travel history among XDR cases — over 82% reported no international travel — is a clear signal that these are not imported cases. This is domestic, community-level transmission happening across American cities right now.

The implications for clinical practice are significant. People experiencing homelessness, men who have sex with men (MSM), and HIV-positive individuals are at dramatically elevated risk, yet awareness of shigellosis as a sexually transmitted infection remains low among healthcare providers, as noted by CDC researchers in 2026. Without proper sexual history-taking and targeted STI co-testing, many XDR Shigella cases go undetected or are treated with antibiotics the bacteria no longer respond to. The CDC has explicitly called on clinicians to consider shigellosis in all cases of acute diarrhea among high-risk groups, and to test for it alongside HIV, syphilis, gonorrhea, and chlamydia where sexual exposure is a factor.

Shigella Outbreak Settings and Transmission in the US 2026 | How Shigella Spreads 2026

Understanding where Shigella outbreaks happen and how the bacteria move from person to person is essential to grasping why this illness remains so stubbornly persistent across the United States.

Source: Frontiers in Public Health, February 2026 — Bajwa, Adegbole & Smith, University of Illinois (CDC NORS data); CDC Clinical Overview of Shigellosis

The transmission data published in February 2026 through the Frontiers in Public Health study provides some of the most comprehensive mapping of how and where Shigella spreads across the United States. Analyzing 1,208 Shigella outbreaks from 2009 to 2022 using CDC NORS data, researchers at the University of Illinois found that childcare settings remain the primary hotspot for outbreak-associated transmission — consistent with what has been known for decades. The outbreak incidence peaked dramatically in 2016 at 0.74 per 1 million population-years before declining steeply through 2022. However, this declining trend in formal outbreak counts should not be mistaken for a reduction in total disease burden, given how many cases remain unreported.

The minimum infectious dose of just 10 to 100 organisms explains why Shigella is uniquely capable of causing explosive outbreaks in congregate settings — whether that’s a daycare, a homeless shelter, or a social network of sexually active adults. Unlike many foodborne pathogens that require millions of bacteria to establish infection, Shigella needs almost nothing to get started. Combined with the fact that infected individuals continue shedding live bacteria in stool for several weeks after their own symptoms have cleared, the window for undetected transmission is wide and dangerous. A person who feels completely recovered may unknowingly infect dozens of others through casual contact, shared surfaces, or food handling.

Shigella Hospitalization and Severity Data in the US 2026 | Shigella Severity Facts 2026

The clinical severity of shigellosis — particularly the XDR variant — is a dimension of this outbreak that deserves focused attention. The numbers below are drawn directly from the CDC’s latest 2026 MMWR report and associated outbreak investigations.

Source: CDC MMWR, April 9, 2026; Spokane Regional Health District Shigella Outbreak Report, March 2024; CDC Clinical Overview of Shigellosis; Kentucky Department of Public Health

The hospitalization rate for XDR Shigella is one of the most important figures in the entire 2026 surveillance dataset. With approximately 37.6% of XDR shigellosis patients requiring hospitalization — as documented in the April 2026 MMWR — this is not a mild illness that people can simply wait out at home. For context, ordinary drug-susceptible shigellosis typically resolves on its own within 5 to 7 days with minimal medical intervention. The XDR variant demands hospital-level resources, specialist input, and IV-administered treatments in the absence of any approved oral option. The real-world severity documented in the Spokane County outbreak (2023–2024) reinforces this: 91 of 201 cases (45.3%) were hospitalized, and the outbreak resulted in 1 confirmed death.

The association between Shigella flexneri and more severe clinical outcomes adds another layer of concern. S. flexneri, which accounts for 34.1% of XDR isolates — nearly double its share in overall US surveillance — is clinically associated with dysentery (bloody, painful diarrhea), higher rates of hospitalization, and greater case-fatality compared to the more common S. sonnei. When this more virulent species combines with XDR resistance and an HIV-positive host, the clinical challenge becomes immense. The annual direct medical cost of $93 million for US shigellosis does not yet fully account for the escalating costs of managing XDR cases, which require longer hospital stays, more intensive workups, and specialist consultations that standard shigellosis does not.

Shigella State-Level Data and Geographic Trends in the US 2026 | Shigella by State 2026

While Shigella affects every corner of the United States, surveillance data consistently shows that certain states bear a disproportionate share of the burden, and certain regional trends have become apparent through CDC reporting.

Source: CDC National Notifiable Diseases Surveillance System (NNDSS); Vax-Before-Travel citing CDC data, 2024–2025; Spokane Regional Health District Outbreak Report, March 2024; Northern Nevada Public Health

California and New York are — and have consistently been — the two states with the highest reported Shigella case counts in the nation. California’s 4,365 cases and New York’s 2,990 cases in the 2024 surveillance window together represent an enormous share of total national burden. This is partly a function of population size, partly a reflection of robust urban surveillance infrastructure, and partly the result of the specific demographic risk factors that are concentrated in these states — including high rates of homelessness in California’s major cities, dense urban populations with known MSM transmission networks, and large volumes of international travel. These are not coincidences; they are the predictable geography of a disease that thrives wherever density, inequality, and limited sanitation access converge.

The Spokane County outbreak (October 2023 – March 2024) is a powerful case study in how quickly Shigella can devastate a local community when conditions allow it. A single case in a person experiencing homelessness led to a community-wide outbreak that eventually reached 201 cases — an extraordinary figure given that Spokane County’s average annual shigellosis count for the five preceding years had been just 3 to 23 cases. With 45.3% of cases requiring hospitalization, this outbreak dramatically illustrates what happens when Shigella finds a vulnerable, closely networked population without robust containment. The subsequent detection of a new cluster in Reno/Washoe County — 14 cases and 9 hospitalizations just months later — is a reminder that these outbreaks do not stay contained to a single geography.

Shigella Outbreak Trends and Annual Percent Change in the US 2026 | Shigellosis Trends 2026

The 2026 peer-reviewed analysis of CDC NORS data spanning 2009 to 2022 gives us the most detailed picture yet of how Shigella outbreak rates have moved over time in the United States, including the key inflection points in that trend.

Source: Frontiers in Public Health, February 12, 2026 — “Temporal Trends of Shigella Outbreaks in the United States, 2009–2022,” Bajwa, Adegbole & Smith, University of Illinois Urbana-Champaign (via CDC NORS data)

The outbreak incidence data tells a compelling rise-and-fall story. From 2009 to 2015, Shigella outbreak rates in the United States climbed at an aggressive annual rate of 25.12%, reaching a peak in 2016 at 0.74 outbreaks per 1 million population-years. After that peak, a steep decline set in — outbreak rates fell by nearly 39% per year from 2015 through 2022, bringing the incidence down to just 0.03 per 1 million population-years by 2022. Researchers attribute part of this post-2016 decline to improved hygiene education and sanitation measures in childcare settings, which have historically been the dominant outbreak venue. However, it must be underscored that declining outbreak incidence does not mean declining total case burden — it largely reflects changes in how and where Shigella is spreading, with the rise of person-to-person and sexual transmission shifting the disease out of traditional formal outbreak clusters and into diffuse, harder-to-track community spread.

The gender nuance in the outbreak data is also worth noting. While XDR shigellosis in 2026 is overwhelmingly male-dominated (86.2% of XDR cases), the broader outbreak-associated case data from 2009 to 2022 shows females with a slightly higher outbreak incidence rate than males — a reflection of women’s disproportionate role as caregivers in childcare settings, which remain the number-one outbreak venue for traditional drug-susceptible strains. This gender inversion between outbreak-associated and XDR cases is one of the clearest signals that two distinct Shigella epidemics are running simultaneously in America in 2026: the traditional pediatric/childcare epidemic, and the emerging adult/sexual network XDR epidemic.

Disclaimer: This research report is compiled from publicly available sources. While reasonable efforts have been made to ensure accuracy, no representation or warranty, express or implied, is given as to the completeness or reliability of the information. We accept no liability for any errors, omissions, losses, or damages of any kind arising from the use of this report.

Email ID:

Please enable JavaScript in your browser to complete this form.

Email

Email *

SUBSCRIBE